Jan. 1, Vol. 29, No. 1

Point of View

The victory of Rep. Henry A. Waxman over Rep. John Dingell for chairman of the House Energy and Commerce Committee on November 21 has raised anxiety levels among analysts and money managers in the healthcare sector. When certain biotech and medtech
...
more »

Feature Articles

The Chinese word for “crisis” is composed of two characters—one for danger and one for opportunity. That analogy sums up, not only the current global situation, but the situation for biotechs in China too, according to speakers at the recent “Pacifi
...
more »

Screening technologies for proteins are still gaining momentum, and as the discipline matures scientists are wondering what technologies are best suited for proteomic profiling. “There’s also a lot of discussion about quantification methodology—what
...
more »

Advances in high-content screening (HCS) instrumentation have significantly increased throughput and improved ease of use such that the technology is moving from its traditional role in secondary screening to the earlier stages of the drug-discovery
...
more »

In a series of recent articles, the restructuring of the global pharmaceutical and biotechnology industry was examined; more specifically, the effect of multinational corporations and Western research institutions, which have invested heavily in maj
...
more »

New technologies and strategies for genetic testing and genomic analysis were the focus of several presentations at the recent American Society of Human Genetics (ASHG) meeting in Philadelphia. Understanding the molecular basis of disease, discernin
...
more »

Industry sources project a continuing 10 to 15% growth in the market for biotherapeutic peptide new chemical entities, and more modest growth of slightly greater than 10% for generic peptides. These projections, however, predate the current global e
...
more »

Stem cell therapy holds great promise for various diseases. In fact, in what many are hailing as a medical milestone, European researchers have successfully transplanted a trachea built from a patient’s own stem cells to replace a failing airway dam
...
more »

One of the hottest research tools these days within the academic, biotech, and pharma communities is DNA microarrays. The concept morphed from the now-classical Southern blotting procedure into the present highly automated systems for screening hund
...
more »

Legal Affairs

The new year will bring many changes and their associated risks and opportunities. With President-elect Barack Obama leading the U.S. through one of the murkiest financial times in history, many are looking toward China in the year of Yi Chou, or th
...
more »

Wall Street BioBeat

Bear Stearns, Merrill Lynch, Lehman Brothers, Washington Mutual, and Wachovia are gone; the government owns AIG, and by the time this article is published we may all own General Motors, Ford, and Chrysler. The economy around us is evolving in ways
...
more »

The Year of Darwin

This year marks the 200th birthday of Charles Darwin (February 12, 1809) and the 150th anniversary of the publication of the Origin of Species . Universities, academic centers, and other scientific organizations all over the globe have a plethora of
...
more »

Tutorials

Hydrolysates (peptones) are widely used in biopharmaceutical manufacturing to enhance cellular growth and production. Ultrafiltration is often utilized to remove large molecular weight entities including endotoxin from hydrolysates. While minimizati
...
more »

The alleviation of pain is perhaps the greatest long-standing goal of both ancient and modern medicine. Quite recently, opiate receptors were implicated in the propagation of pain. With exquisite complimentary molecular architecture, these protein p
...
more »

Corporate Profile

Today, about one-third of the world’s population, or two billion people, carry the tuberculosis (TB) bacteria, although most never develop active TB disease. Studies estimate that 65 to 70 million people have active TB, there are 8 to 10 million new
...
more »

BioMarket Trends

Protein-based therapeutics may be moving from a second-string opportunity to a first-draft prospect. The market for protein-based therapeutics is significant and growing at a rate that is well above what one would call average for the therapeutics/p
...
more »

Assay Tutorials

ZyGEM’s technologies are derived from a collection of extremophiles that thrive in extreme temperature and pH conditions. The company’s DNA-extraction technology is based on Erebus Antarctica 1 (EA1), an active metallo-endo proteinase from a Bacilli
...
more »

Sidebars

The Beijing Institute of Genomics (BIG) of the Chinese Academy of Sciences has acquired eight additional Life Technologies’ SOLiD™ Systems for a variety of genomics studies. The SOLiD System is the company’s next-generation genomic analysis platfor
...
more »

A number of HCS vendors will be launching software packages to go along with their instrument portfolios at “High Content Screening’s” Technology Showcase. According to Mark Collins, marketing manager for cellular imaging at Thermo Fisher Scientific
...
more »

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

GEN Poll

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

56.6%

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.